Glenmark profit may miss estimates - StarMine

Reuters Market Eye - Glenmark Pharmaceuticals may lag consensus profit forecast for the October-December quarter when it reports results later in the day, Thomson Reuters StarMine's SmartEstimates shows.

StarMine's SmartEstimates, which places greater emphasis on forecasts by top-rated analysts, expects Glenmark to report a profit of 1.77 billion rupees for the quarter, compared with a consensus mean estimate of 1.81 billion rupees.

Glenmark shares are up 0.4 percent.

(Reporting by Abhishek Vishnoi)